Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8-week open-label escitalopram treatment for post-stroke depression
ChiCTR1800019366Phase 4Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of escitalopram in major depressive disorder (MDD) (2 cohorts), sponsored by Beijing Tiantan Hospital. Primary endpoint: Change from baseline in Stroke Aphasic Depression Questionnaire-Hospital score at week 8. Started Nov 2018; status: recruiting.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1800019366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019366.